Motus GI Holdings, Inc. · OTC:MOTS

Motus GI — Investor Presentation (October 2022)

19 slides from Motus GI's investor presentation, October 2022

  1. Slide 1: Breakthrough Solutions for GI Endoscopy

    Breakthrough Solutions for GI Endoscopy October 2022

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company’s product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, bu

  3. Slide 3: Motus GI

    Motus GI Patented First Mover Our mission is to provide Advantage innovative solutions in GI Robust Significant endoscopy that improve patient Clinical Growth outcomes and experiences. Data Opportunities Large Global Experienced Addressable Leadership Market Team Motus GI | Breakthrough Solutions fo

  4. Slide 4: Executive Leadership Team

    Executive Leadership Team Timothy P. Moran I Chief Executive Officer, Board Director Mark Pomeranz I President & Chief Operating Officer Andrew L. Taylor, MBA I Chief Financial Officer Scott C. Aldrich Jr. I VP, Global Marketing & Strategy Jeff Hutchison I VP, US Sales & Commercial Operations Ravit

  5. Slide 5: Large Global Market Opportunity

    Large Global Market Opportunity >54M 1 o Insufficient Bowel Prep prior to colonoscopy is a universal problem that can result in missed pathology, global colonoscopy delayed and aborted procedures, procedures Annually missed pathology, and more frequent than necessary procedure intervals >20M 1 o The

  6. Slide 6: A Closer Look at the US Opportunity

    A Closer Look at the US Opportunity 2022 2023 2024 6.2M 2 INPATIENT INPATIENT INPATIENT COLONOSCOPY COLONOSCOPY COLONOSCOPY Annual Procedures EXPANDED HOSPITAL-BASED TARGETED OUTPATIENT $6.2B HOSPITAL-BASED HOSPITAL-BASED * OUTPATIENT COLONOSCOPY OUTPATIENT COLONOSCOPY COLONOSCOPY ASC-BASED Total Ad

  7. Slide 7: Inpatient Colonoscopy | The Unmet Need

    Inpatient Colonoscopy | The Unmet Need Insufficient bowel prep can lead to unnecessary extended hospitalizations LOWER GI BLEEDS 4 ~$2,298 SEVERE ANEMIA per night of unrecoverable bed ABDOMINAL PAIN 3 costs per patient INFECTION Pain Point Clinical Impact • Increased Length of stay • Delayed Therapy

  8. Slide 8: Outpatient Colonoscopy | The Unmet Need

    Outpatient Colonoscopy | The Unmet Need Patient Pathway: Current Standard of Care UP TO 50% DO NOT SHORTENED INTERVAL < 1 YEAR RETURN FOR Up to 6 COLONOSCOPY 22% 5 increase in Pain direct cost of Point colonoscopy Clinical Impact • Lower adenoma detection rates • Prolonged procedures • Increased adv

  9. Slide 9: Our Solution | Novel Technology Ensures Visualization

    Our Solution | Novel Technology Ensures Visualization The Pure-Vu EVS system is indicated to help facilitate the cleaning of a poorly prepared GI tract during an endoscopy procedure. Motus GI | Breakthrough Solutions for GI Endoscopy 9

  10. Slide 10: Our Solution | Novel Technology Ensures Visualization

    Our Solution | Novel Technology Ensures Visualization 32 Granted Patents/27 Pending Worldwide PULSED VORTEX SMART SENSE SMOOTH GLIDE IRRIGATION SUCTION NAVIGATION Motus GI | Breakthrough Solutions for GI Endoscopy 10

  11. Slide 11: Pure-Vu EVS System Pricing

    Pure-Vu® EVS System Pricing Pure-Vu® EVS Pure-Vu® EVS Workstation Distal Oversleeve Purchase 5 per box Lease One sleeve fits standard and slim Rental colonoscopes Tiered pricing $75,000 / Workstation $1,100 / Sleeve Motus GI | Breakthrough Solutions for GI Endoscopy 11

  12. Slide 12: Pure-Vu Consistently Demonstrates Effective Intraprocedural Cleansing

    Pure-Vu Consistently Demonstrates Effective Intraprocedural Cleansing in Patients with IBP 4 STUDIES In three multi-centered and one single-center studies, patients presenting with an inadequately prepped colon 3 PEER-REVIEWED (as determined by the Boston Bowel Preparation Scale) COMPLETED became ad

  13. Slide 13: Clinical Study to Advance Reimbursement Efforts

    Clinical Study to Advance Reimbursement Efforts Study Objective Sample Size The objective of this study is to demonstrate that when Total Sample Size: ~1,000 patients / 115 subjects Pure-Vu EVS System is used to salvage inadequately getting Pure-Vu prepped colons, the overall rate of inadequate OCs

  14. Slide 14: US Hospital Commercial Expansion

    US Hospital Commercial Expansion EXPANDED COMMERCIAL FOOTPRINT Extended Reach Broader Targeting Deeper Penetration o Expanded Salesforce o Academic Medical Centers o General GI Physicians o Partnership o VA Medical Centers o Rescue Procedures development o Community Hospitals o Targeted Hospital o I

  15. Slide 15: Strategic Growth Opportunities

    Strategic Growth Opportunities Upper GI Indication International Expansion UGI bleeds occur at a rate of approximately Distribution and Licensing Partnerships 400K 8 CE mark efforts under way for cases per year in the US Pure-Vu EVS - Q4 2023 ~34M 10 The mortality rate of this condition 9 is up to ~

  16. Slide 16: Key Upcoming Catalysts

    Key Upcoming Sequential quarterly revenue growth Catalysts Pure-Vu EVS Upper GI regulatory submission for indication expansion Large multi-center study supporting outpatient reimbursement submission Expansion Outside the US Motus GI | Breakthrough Solutions for GI Endoscopy 16

  17. Slide 17: Follow Our Journey. Share in Our Success.

    Follow Our Journey. Share in Our Success.

  18. Slide 18: Board of Directors

    Board of Directors David Hochman | Chairman Chairman & CEO, Orchestra BioMed; Director of Corbus and Adgero Shervin Korangy | Director President and Chief Executive Officer of Beaver-Visitec International Timothy P. Moran | Chief Executive Officer and Director Seasoned commercial and operating execu

  19. Slide 19: References

    References Slide Reference 5 1. Estimate for calendar year 2021, based on Motus review and analysis of 2019 inpatient market data and 2021 projections for the U.S., as obtained from iData Research Inc. 2. Estimate for calendar year 2021, based on Motus review and analysis of 2019 inpatient market da

Motus GI Holdings — Investor Presentation (October 2022) on 6ix